doi: 10.1128/AAC.43.7.1808.
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations
Affiliations
- PMID: 10390251
- PMCID: PMC89372
- DOI: 10.1128/AAC.43.7.1808
Item in Clipboard
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations
Antimicrob Agents Chemother.
1999 Jul.
Abstract
The susceptibilities of six Chlamydia pneumoniae type strains and of six German patient isolates to erythromycin, azithromycin, roxithromycin, clarithromycin, doxycycline, ofloxacin, and rifampin were investigated. MICs and minimal chlamydicidal concentrations were all within the ranges reported previously. Combinations of azithromycin with either ofloxacin, doxycycline, or rifampin, as well as combinations of three antibiotics (rifampin, azithromycin, and ofloxacin or doxycycline), showed synergistic activity against C. pneumoniae.
Similar articles
-
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573. Antimicrob Agents Chemother. 1992. PMID: 1324650 Free PMC article.
-
In vitro activity of trovafloxacin against Chlamydia pneumoniae.Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033. Antimicrob Agents Chemother. 1997. PMID: 9303410 Free PMC article.
-
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212. Antimicrob Agents Chemother. 1996. PMID: 8787907 Free PMC article.
-
[Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].Acta Med Croatica. 2004;58(4):329-33. Acta Med Croatica. 2004. PMID: 15700690 Review. Croatian.
-
Potential for antimicrobial resistance in Chlamydia pneumoniae.J Infect Dis. 2000 Jun;181 Suppl 3:S456-9. doi: 10.1086/315608. J Infect Dis. 2000. PMID: 10839739 Review.
Cited by
-
Chlamydia pneumoniae Infection and Inflammatory Diseases.For Immunopathol Dis Therap. 2016;7(3-4):237-254. doi: 10.1615/ForumImmunDisTher.2017020161. For Immunopathol Dis Therap. 2016. PMID: 30687565 Free PMC article.
-
Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients.3 Biotech. 2016 Dec;6(2):166. doi: 10.1007/s13205-016-0473-z. Epub 2016 Aug 11. 3 Biotech. 2016. PMID: 28330238 Free PMC article.
-
Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.Antimicrob Agents Chemother. 2005 Mar;49(3):903-7. doi: 10.1128/AAC.49.3.903-907.2005. Antimicrob Agents Chemother. 2005. PMID: 15728882 Free PMC article.
-
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.Antimicrob Agents Chemother. 2003 Mar;47(3):1135-6. doi: 10.1128/AAC.47.3.1135-1136.2003. Antimicrob Agents Chemother. 2003. PMID: 12604555 Free PMC article.
References
-
- Beale A S, Masson N D. Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection. J Antimicrob Chemother. 1994;34:1072–1074. - PubMed
-
- Block S, Hedrick J, Hammerschlag M R, Cassell G H, Craft J C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J. 1995;14:471–477. - PubMed
-
- Eliopoulos G M, Moellering R C., Jr . Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Md: Williams & Wilkins; 1996. pp. 330–393.
-
- Falck G, Gnarpe J, Gnarpe H. Persistent Chlamydia pneumoniae infection in a Swedish family. Scand J Infect Dis. 1996;28:271–273. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
